CA2964428C - Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals - Google Patents

Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals Download PDF

Info

Publication number
CA2964428C
CA2964428C CA2964428A CA2964428A CA2964428C CA 2964428 C CA2964428 C CA 2964428C CA 2964428 A CA2964428 A CA 2964428A CA 2964428 A CA2964428 A CA 2964428A CA 2964428 C CA2964428 C CA 2964428C
Authority
CA
Canada
Prior art keywords
derived
mammals
pyrazoline
joint disease
degenerative joint
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2964428A
Other languages
English (en)
French (fr)
Other versions
CA2964428A1 (en
Inventor
Josep Homedes-Beguer
David Sabate-Elias
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ecuphar Nv
Original Assignee
Ecuphar Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ecuphar Nv filed Critical Ecuphar Nv
Publication of CA2964428A1 publication Critical patent/CA2964428A1/en
Application granted granted Critical
Publication of CA2964428C publication Critical patent/CA2964428C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CA2964428A 2014-10-16 2015-10-13 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals Active CA2964428C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP14382396.1A EP3009137A1 (en) 2014-10-16 2014-10-16 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals
EP14382396.1 2014-10-16
PCT/EP2015/073635 WO2016059028A1 (en) 2014-10-16 2015-10-13 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals

Publications (2)

Publication Number Publication Date
CA2964428A1 CA2964428A1 (en) 2016-04-21
CA2964428C true CA2964428C (en) 2022-01-04

Family

ID=51844648

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2964428A Active CA2964428C (en) 2014-10-16 2015-10-13 Pyrazoline-derived compound and its use in a weekly dosage regime against inflammation and pain derived from degenerative joint disease in mammals

Country Status (20)

Country Link
US (1) US11154536B2 (enExample)
EP (2) EP3009137A1 (enExample)
JP (1) JP6655625B2 (enExample)
CN (2) CN115154465A (enExample)
AR (1) AR102295A1 (enExample)
CA (1) CA2964428C (enExample)
CY (1) CY1123243T1 (enExample)
DK (1) DK3206684T3 (enExample)
ES (1) ES2828435T3 (enExample)
HR (1) HRP20201233T1 (enExample)
HU (1) HUE050511T2 (enExample)
LT (1) LT3206684T (enExample)
MX (1) MX376725B (enExample)
PL (1) PL3206684T3 (enExample)
PT (1) PT3206684T (enExample)
RS (1) RS60777B1 (enExample)
SI (1) SI3206684T1 (enExample)
SM (1) SMT202000415T1 (enExample)
TW (1) TWI707678B (enExample)
WO (1) WO2016059028A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109303784B (zh) * 2018-09-30 2020-06-23 山东省文登整骨医院 痛风性关节炎动物模型的构建方法
TWI875757B (zh) * 2019-05-08 2025-03-11 瑞士商諾華公司 T1dm和胰島炎治療中使用之抗cd40抗體
EP4029502A1 (en) 2021-01-15 2022-07-20 Ecuphar N.V. Pyrazoline-derived compound (enflicoxib) for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals
US12208085B2 (en) 2022-05-31 2025-01-28 Ecuphar Nv Pyrazoline-derived compound for use in the prevention and/or treatment of pain and inflammation associated to surgery in mammals

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU773615B2 (en) * 1997-05-05 2004-05-27 Pfizer Inc. COX-2 selective carprofen for treating pain and inflammation in dogs
ES2137138B1 (es) 1998-05-29 2000-09-16 Esteve Labor Dr Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos.
US20050131028A1 (en) * 2003-09-11 2005-06-16 Pharmacia Corporation Methods and compositions for the extended duration treatment of pain, inflammation and inflammation-related disorders
CN101175769A (zh) * 2005-03-10 2008-05-07 健泰科生物技术公司 用于调控血管完整性的方法和组合物

Also Published As

Publication number Publication date
DK3206684T3 (da) 2020-08-10
HRP20201233T1 (hr) 2020-11-13
CN115154465A (zh) 2022-10-11
MX376725B (es) 2025-03-07
TWI707678B (zh) 2020-10-21
PL3206684T3 (pl) 2021-01-11
WO2016059028A1 (en) 2016-04-21
EP3206684A1 (en) 2017-08-23
AR102295A1 (es) 2017-02-15
HUE050511T2 (hu) 2020-12-28
ES2828435T3 (es) 2021-05-26
CY1123243T1 (el) 2021-10-29
JP6655625B2 (ja) 2020-02-26
CN107257684A (zh) 2017-10-17
PT3206684T (pt) 2020-08-24
EP3009137A1 (en) 2016-04-20
TW201625239A (zh) 2016-07-16
CA2964428A1 (en) 2016-04-21
JP2017531042A (ja) 2017-10-19
LT3206684T (lt) 2020-10-12
SI3206684T1 (sl) 2020-11-30
US20170231961A1 (en) 2017-08-17
US11154536B2 (en) 2021-10-26
EP3206684B1 (en) 2020-06-17
RS60777B1 (sr) 2020-10-30
MX2017004899A (es) 2018-02-12
SMT202000415T1 (it) 2020-11-10

Similar Documents

Publication Publication Date Title
EP3481402A4 (en) CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
EP3448874A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3448987A4 (en) COMPOSITIONS FOR TREATING A DISEASE
EP3180009A4 (en) Zoledronic acid dosage forms for the treatment of pain
IL264156A (en) Compounds, preparations and methods for treating the disease
EP3675859A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF A DISEASE
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
WO2015168466A8 (en) Inhibitors of lysine specific demethylase-1
WO2015023976A3 (en) Selective grp94 inhibitors and uses thereof
MX2016012574A (es) Compuestos heteroarilo sustituidos y metodos de uso.
IL266047A (en) Methods and preparations for the treatment of Fabry disease
WO2015171558A3 (en) BENZENESULFONAMIDO AND RELATED COMPOUNDS FOR USE AS AGONISTS OF RORγ AND THE TREATEMENT OF DISEASE
HK1243935A1 (zh) 有机化合物
EP3102220C0 (en) SYNERGIC FOOD SUPPLEMENT COMPOSITIONS FOR THE PREVENTION, TREATMENT OR REGULATION OF INFLAMMATORY DISORDERS
EP3206685A4 (en) Prevention or treatment of sleep disorders using dexmedetomidine formulation
NZ728796A (en) Aqueous formulation comprising paracetamol and ibuprofen
EA201690783A1 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
CL2014002845A1 (es) Compuestos derivados de pirazol inhibidores de sglt1; metodo para tratar la diabetes; composicion farmaceutica; uso del compuesto para el tratamiento de la diabetes tipo 1 y tipo 2.
WO2016080796A3 (ko) 세스퀴테르펜 화합물을 포함하는, stat3 매개 질환의 예방 또는 치료용 약학적 조성물 및 이의 용도
CY1123243T1 (el) Ενωση προερχομενη απο πυραζολινη και η χρηση τησσε ενα θεραπευτικο σχημα εβδομαδιαιας δοσολογησης εναντια στην φλεγμονη και τον πονο που προερχονται απο την εκφυλιστικη ασθενεια των αρθρωσεων στα θηλαστικα
ZA201904591B (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs
WO2015001541A3 (en) Pharmaceutical film composition
EA033297B1 (ru) Терапевтические и питательные композиции для функциональных нарушений работы пищеварительной системы
HK1243936A1 (zh) 有机化合物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20190103